Latest update on Euroneut41 Project- HIV Vaccine
The Surrey Clinical Research Centre was recently at the centre of an international effort with European Commission funding to design and test a vaccine to prevent HIV/AIDS. The vaccine employed several highly innovative concepts including nasal delivery to produce strong genital tract immunity, liposomal formulation, and an uniquely designed active component to make virus-blocking antibodies. The SCRC conducted the first in human clinical trial of this product, drawing on its extensive expertise in translational medicine, mucosal immunology, and Phase 1 trial accreditation. A short video was made about the EURONEUT41 project by the European Commission as part of its initiative to enhance awareness of cutting-edge EU sponsored research in high priority areas of medical need.